Cargando…
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
BACKGROUND: This is a real-world evidence study that aims to analyze the efficacy, tolerability and safety profile of paritaprevir/ombitasvir/ritonavir and dasabuvir, in patients with renal impairment. METHODS: We conducted an observational prospective study, on 232 patients with chronic kidney dise...
Autores principales: | Iliescu, Elena Laura, Mercan-Stanciu, Adriana, Toma, Letitia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966843/ https://www.ncbi.nlm.nih.gov/pubmed/31948406 http://dx.doi.org/10.1186/s12882-020-1687-1 |
Ejemplares similares
-
Correlation Between Serum Alpha-Fetoprotein and Tumour Size in Patients With Hepatocellular Carcinoma Treated With Direct-Acting Antivirals
por: Rusie, Daniel, et al.
Publicado: (2022) -
Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals
por: Mercan-Stanciu, Adriana, et al.
Publicado: (2022) -
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania
por: Bacinschi, Xenia, et al.
Publicado: (2022) -
Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
por: Ryu, Ji Eun, et al.
Publicado: (2022) -
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
por: Lin, Ming V., et al.
Publicado: (2016)